Advanced Esophageal Squamous Carcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma
Conditions
Brief summary
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma
Detailed description
Dr. Bin Wang developed the investigational vaccine used in this clinical trial and designed the trial protocol.For patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma tumor who have disease progression with first line chemotherapy. Single or multiple doses of personalized mRNA tumor vaccine encoding neoantigen will be given to observe the safety and efficacy the mRNA tumor vaccine. Primary objectives: Determine the safety, tolerability and cytokinetics of the personalized mRNA tumor vaccine in patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma. Secondary objectives: Make a preliminary evaluation on the efficacy of personalized mRNA tumor vaccine in patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma with the following parameters: Time of tumor progression (TTP); Disease Control Rate (DCR); Objective Remission Rate (ORR); Overall Survival (OS).
Interventions
BIOLOGICALPersonalized mRNA Tumor Vaccine
subcutaneous injection with personalized mRNA tumor vaccine at least four times
Sponsors
Stemirna Therapeutics
Changhai Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18 - 75 with pathologically confirmed advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma. 2. Patients with advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma who have disease progression with first line chemotherapy. (1) Failure of treatment is defined as disease progression, recurrence or metastatic disease, or intolerable toxicities occurred after treatment. (2) Each line of treatment during the period of disease progression includes one or more chemotherapy drugs which are administered for not less than one cycle or even longer. Neoadjuvant/adjuvant therapy can be applied at an earlier stage of treatment. If patient has developed recurrence or metastatic disease within 24 weeks of neoadjuvant/adjuvant therapy, it is considered as one line of systemic chemotherapy. (3) Therapies that can be performed at an earlier stage are chemotherapy in conjunction with molecular targeted drugs. 3. Expected survival after first dose of study drug \> 24 weeks. 4. At least one measurable lesion (≥ 10 mm) for imaging assessment. 5. ECOG scores 0 - 1. 6. Fresh pathological tissue specimens can be obtained 7. White blood cells (WBCs) ≥ 2.5×10\^9/L * Platelets (PLT) ≥ 100×10\^9/L * Hemoglobin, Blood (Hb) ≥ 9.0 g/dL * MID ≥ 1.5×10\^9/L * Lymphocyte (LY) ≥ 0.47×10\^9/L * LY% ≥ 15% 8. Serum albumin (Alb) ≥ 30 g/L 9. Serum lipase (LPS) and serum amylase \< 1.5 ULN 10. Serum creatinine ≤ 1.5 ULN 11. Alanine aminotransferase (ALT) ≤ 2.5 ULN * Aspartate aminotransferase (AST) ≤ 2.5 ULN * If osseous metastasis or liver metastasis is developed and alkaline phosphatase • (ALP) \> 2.5 ULN, ALT and AST \< 1.5 ULN. 12. Serum total bilirubin (TBIL) ≤ 1.5 ULN 13. Prothrombin Time (PT): International Normalized Ratio (INR) \< 1.7. * PT \< (ULN + 4) s All test results should be within their normal ranges, and the patient is not receiving continuous supportive care.
Exclusion criteria
Patients with any of the following conditions are not eligible for the study. 1. Pregnant or lactating women. 2. HIV positive, HCV positive, HBV DNA copies ≥ 10\^3. 3. Uncontrolled active infection. 4. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary. 5. Allergic to immunotherapies and related drugs. 6. Untreated brain metastases or having symptoms of brain metastases. 7. Metastases to the lung: central tumor or multiple metastases. 8. Patients with heart disease for which treatment is needed or with poorly controlled hypertension. 9. Patients with unstable or active peptic ulcer or with alimentary tract hemorrhage. 10. Patients with previous organ transplantation or in preparation for organ transplantation. 11. Patients have undertaken major surgeries or have been badly injured 4 weeks before the study (blood collection), or will undertake major surgeries during the study. 12. The judgment of investigators that the patient is not able to or not willing to follow the instructions of the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 24 weeks | During the trial conduction, especially within the 24 weeks of treatment phase when mRNA tumor Vaccine administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all ≥ grade 3 adverse events per CTCAE (v 3.0) will be recorded, including but not limited to the toxicities potentially suspected to relate to injection procedures and/or mRNA Tumor Vaccine therapy as listed below: * Fever * Chills * Nausea, vomiting and other gastrointestinal symptoms * Fatigue * Hypotension * Respiratory distress * Tumor lysis syndrome * Neutropenia, thrombocytopenia * Liver and kidney dysfunction |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate of Personalized mRNA Tumor Vaccine | 1.5 years | Disease Control Rate (DCR) |
| Progression-free Survival of Personalized mRNA Tumor Vaccine | 2 years | Progression-free Survival (PFS) |
| Time to Tumor Progression of Personalized mRNA Tumor Vaccine | 2 years | Time to Tumor Progression (TTP) |
| Overall Survival of Personalized mRNA Tumor Vaccine | 3 years | Overall Survival (OS) |
Countries
China
Contacts
Primary ContactBin Wang, Dr.
Backup ContactXianbao Zhan, Dr.
Outcome results
None listed